Cannapharmarx, Inc. (CPMD): Operating Cash Flow
-$789.1K
Year ended 2025-12-31
-$112.3K
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$789.1K | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$1.70M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$2.27M | n/m | 2025-04-10, From 2023-01-01 |
| 2022-12-31 | -$1.45M | n/m | 2023-09-01, From 2022-01-01 |
| 2021-12-31 | -$2.41M | n/m | 2023-09-01, From 2021-01-01 |
| 2020-12-31 | -$563.6K | n/m | 2022-04-15, From 2020-01-01 |
| 2019-12-31 | -$3.79M | n/m | 2021-04-14, From 2019-01-01 |
| 2018-12-31 | -$941.1K | n/a | 2020-05-27, From 2018-01-01 |
| 2017-12-31 | $0 | n/m | 2019-04-03, From 2017-01-01 |
| 2016-12-31 | -$22.4K | n/m | 2018-09-14, From 2016-01-01 |
| 2015-12-31 | -$2.55M | n/m | 2018-09-14, From 2015-01-01 |
| 2014-12-31 | -$1.54M | n/m | 2018-09-11, From 2014-01-01 |
| 2013-12-31 | -$11.0K | n/m | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | -$10.9K | n/m | 2013-03-28, From 2012-01-01 |
| 2011-12-31 | -$12.1K | n/a | 2013-03-28, From 2011-01-01 |
| 2010-12-31 | $0 | n/m | 2012-03-14, From 2010-01-01 |
| 2009-12-31 | -$69.1K | n/a | 2011-06-30, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$789.1K | n/m |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$44.76M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | -$1.83M | n/m |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$14.11M | n/m |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | -$4.79M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$66.44M | n/m |
| Longeveron Inc. (LGVN) | 2025-12-31 | -$18.64M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$12.35M | n/m |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2026-03-31 | -$4.02M | n/m |
Compare CPMD, NWBO, ATXI, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗